3-methylglutaconic aciduria type 3
three-methyl-glue-ta-conic aciduria type three
Also known as: Costeff Syndrome, Optic Atrophy Plus Syndrome
At a Glance
What is 3-methylglutaconic aciduria type 3?
3-methylglutaconic aciduria type 3 is a rare genetic disorder that primarily affects the nervous system and vision. It is caused by mutations in the OPA3 gene, leading to the accumulation of 3-methylglutaconic acid in the body. Over time, individuals experience progressive vision loss due to optic atrophy, along with movement disorders and developmental delays. Early symptoms often include difficulty with coordination and balance, while later symptoms can involve more severe neurological impairments. Early diagnosis is crucial for managing symptoms and improving quality of life. The condition can significantly impact family life, requiring ongoing medical care and support. Prognosis varies, but many individuals maintain a degree of independence with appropriate interventions. Daily life for affected individuals may involve regular medical appointments, vision aids, and physical therapy. Despite challenges, many lead fulfilling lives with the support of family and healthcare providers. The disorder is more prevalent in certain populations, such as Iraqi Jews, due to genetic factors. Awareness and understanding of the condition are essential for early intervention and management.
Medical Definition
3-methylglutaconic aciduria type 3 is a metabolic disorder characterized by elevated levels of 3-methylglutaconic acid due to defects in the OPA3 gene. Pathologically, it involves mitochondrial dysfunction leading to optic atrophy and neurological symptoms. Histological findings may show degeneration of the optic nerve fibers. It is classified under mitochondrial disorders with a specific focus on optic atrophy plus syndromes. Epidemiologically, it is more common in the Iraqi Jewish population, highlighting a founder effect. The disease course is progressive, with symptoms worsening over time but manageable with supportive care.
3-methylglutaconic aciduria type 3 Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Optic atrophy manifests as a progressive loss of vision due to the degeneration of the optic nerve. This occurs because of mitochondrial dysfunction leading to impaired energy production in the optic nerve cells. Over time, the vision loss can become severe, potentially leading to blindness. It significantly impacts daily life by hindering the ability to perform tasks that require clear vision, and management may include visual aids and supportive therapies.
Developmental delay is characterized by a slower than expected progression in achieving developmental milestones such as walking and talking. This is caused by impaired cellular energy production affecting brain development and function. As the child grows, the delay may become more apparent, impacting learning and social interactions. Early intervention with therapies can help improve skills and support development.
Movement disorders present as abnormal involuntary movements or difficulty in coordinating voluntary movements. These are due to disruptions in the basal ganglia and cerebellum caused by mitochondrial dysfunction. Over time, these disorders may worsen, affecting mobility and coordination. Physical and occupational therapies can help manage symptoms and improve quality of life.
Common
Hearing loss in this condition can range from mild to severe and is often sensorineural in nature. It results from damage to the auditory nerves or inner ear structures due to mitochondrial dysfunction. The progression can vary, with some individuals experiencing gradual worsening. Hearing aids and cochlear implants can assist in improving hearing ability and communication.
Muscle weakness is characterized by reduced strength and endurance in the muscles. This occurs because of insufficient energy production in muscle cells due to mitochondrial defects. Over time, weakness can lead to difficulties in performing physical activities and may contribute to fatigue. Physical therapy and exercise programs can help maintain muscle strength and function.
Ataxia manifests as a lack of voluntary coordination of muscle movements, leading to unsteady and clumsy motion. It is caused by dysfunction in the cerebellum, which is affected by mitochondrial energy deficits. The condition may progressively worsen, impacting gait and balance. Supportive therapies and mobility aids can help manage symptoms and prevent falls.
Less Common
Seizures in this condition can vary in type and severity, often resulting from abnormal electrical activity in the brain. Mitochondrial dysfunction can lead to neuronal hyperexcitability, triggering seizures. The frequency and intensity of seizures may change over time, requiring ongoing management. Antiepileptic medications and regular monitoring are essential for controlling seizure activity.
Cognitive impairment involves difficulties with memory, attention, and problem-solving skills. This arises from mitochondrial dysfunction affecting brain cells, leading to impaired cognitive processing. The degree of impairment can vary, potentially worsening with age. Cognitive therapies and educational support can help manage symptoms and improve cognitive function.
What Causes 3-methylglutaconic aciduria type 3?
3-Methylglutaconic aciduria type 3, also known as Costeff Syndrome, is primarily caused by mutations in the OPA3 gene located on chromosome 19q13.2. The OPA3 gene encodes a protein that is involved in mitochondrial function, particularly in maintaining mitochondrial integrity and energy production. Mutations in OPA3 lead to structural changes in the protein, impairing its ability to maintain mitochondrial membrane potential and ATP synthesis. This disruption results in mitochondrial dysfunction, characterized by impaired oxidative phosphorylation and increased production of reactive oxygen species. Consequently, cells experience energy deficits and oxidative stress, particularly affecting high-energy-demand tissues such as the optic nerve and brain. The accumulation of 3-methylglutaconic acid and other metabolites further exacerbates cellular dysfunction, leading to neurodegeneration. Neuroinflammation is triggered as a secondary response, contributing to progressive damage in neural tissues. White matter degeneration occurs due to demyelination and loss of oligodendrocytes, disrupting neural transmission. Symptoms such as optic atrophy, movement disorders, and cognitive decline emerge due to the specific vulnerability of neural tissues to energy deficits and oxidative damage. The pattern of symptom onset and progression is influenced by the degree of mitochondrial dysfunction and the specific neural circuits affected. Variability in disease severity among patients is attributed to differences in the extent of mitochondrial impairment and genetic background. Environmental factors and additional genetic modifiers may also play a role in phenotypic variability. Understanding these molecular and cellular mechanisms is crucial for developing targeted therapies for Costeff Syndrome.
How is 3-methylglutaconic aciduria type 3 Diagnosed?
Typical age of diagnosis: Diagnosis of 3-methylglutaconic aciduria type 3, also known as Costeff Syndrome, typically occurs in early childhood when symptoms such as visual impairment and developmental delay become apparent. Diagnosis may be delayed in cases where symptoms are mild or non-specific.
Clinicians look for key symptoms such as optic atrophy, movement disorders, and developmental delays. A detailed family history is important, especially in populations with known genetic predispositions. Physical examination may reveal signs of neurological impairment and muscle weakness. This step helps to identify the need for further diagnostic testing and rule out other conditions with similar presentations.
Magnetic Resonance Imaging (MRI) is the preferred modality to assess brain structure. Specific abnormalities such as cerebellar atrophy and white matter changes may be visible. These findings support the diagnosis of Costeff Syndrome by correlating clinical symptoms with structural brain changes. Imaging also helps exclude other neurodegenerative disorders that may present similarly.
Urine organic acid analysis is ordered to detect elevated levels of 3-methylglutaconic acid. Biomarkers such as increased 3-methylglutaric acid and 3-methylglutaconic acid are sought. Abnormal results show elevated excretion of these acids, confirming metabolic dysfunction. These results guide the clinician to consider genetic testing for definitive diagnosis.
The OPA3 gene is sequenced to identify pathogenic mutations. Mutations such as missense or nonsense changes are typically found. Positive results confirm the diagnosis of 3-methylglutaconic aciduria type 3. Genetic findings inform family counseling regarding inheritance patterns and recurrence risks.
3-methylglutaconic aciduria type 3 Treatment Options
Coenzyme Q10 is an antioxidant used in an attempt to improve mitochondrial function. Its mechanism involves supporting cellular energy production. Despite its use, clinical evidence for efficacy in 3-methylglutaconic aciduria type 3 is limited, as studies have shown ineffectiveness. Side effects are generally mild but may include gastrointestinal discomfort. The limitations highlight the need for alternative therapeutic strategies.
Techniques such as strength training and balance exercises are employed. The goal is to improve motor function and prevent contractures. Sessions are typically conducted 2-3 times per week, lasting 30-60 minutes each. Measurable outcomes include improved mobility and reduced fall risk. Long-term benefits include enhanced quality of life and independence.
Surgery may be indicated for severe musculoskeletal deformities. Procedures such as tendon release or spinal fusion may be performed. Expected benefits include improved mobility and pain relief. Surgical risks include infection and anesthesia complications. Post-operative care involves rehabilitation and monitoring for complications.
The care team typically includes neurologists, geneticists, and physical therapists. Interventions focus on symptom management and functional support. Psychosocial support strategies involve counseling and community resources. Family education is crucial for understanding the condition and managing daily challenges. Long-term monitoring includes regular follow-ups to assess disease progression and adjust care plans.
When to See a Doctor for 3-methylglutaconic aciduria type 3
- Severe vision loss — This could indicate rapid progression of optic atrophy, requiring immediate medical evaluation.
- Acute neurological decline — Sudden worsening of neurological symptoms may suggest a critical complication needing urgent intervention.
- Severe muscle weakness — This could impair breathing or mobility, necessitating emergency medical attention.
- Progressive vision impairment — Gradual worsening of vision should be assessed by an ophthalmologist to manage optic atrophy.
- Increasing difficulty with coordination — This may indicate worsening neurological function and should be evaluated by a neurologist.
- Persistent fatigue — Could suggest metabolic imbalance or mitochondrial dysfunction, warranting further investigation.
- Mild vision changes — Monitor for any progression and report to a healthcare provider during regular check-ups.
- Occasional muscle cramps — Keep track of frequency and intensity, and discuss with a doctor if they worsen.
3-methylglutaconic aciduria type 3 — Frequently Asked Questions
Is this condition hereditary?
3-Methylglutaconic aciduria type 3 is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. Parents of an individual with this condition are typically carriers, having one mutated gene copy but usually not showing symptoms. There is a 25% chance with each pregnancy for carrier parents to have an affected child. De novo mutations are not common in this condition. Genetic counseling is recommended for affected families to understand inheritance patterns and carrier testing.
What is the life expectancy for someone with this condition?
Life expectancy can vary significantly based on the severity and management of symptoms. Early onset is generally associated with a more severe prognosis, while later onset may result in a milder course. Mortality is often related to complications such as severe neurological decline or metabolic crises. Effective management of symptoms and complications can improve quality of life and potentially extend life expectancy. Realistic expectations should include ongoing medical care and supportive therapies.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves a combination of clinical evaluation, biochemical tests showing elevated 3-methylglutaconic acid levels, and genetic testing. The time from first symptoms to diagnosis can vary, often taking several months to years due to the rarity of the condition. Specialists such as geneticists, neurologists, and metabolic specialists are usually involved. Delayed diagnosis is common due to symptom overlap with other conditions and lack of awareness. Confirmation is achieved through genetic testing identifying mutations in the OPA3 gene.
Are there any new treatments or clinical trials available?
Research is ongoing, with some promising studies focusing on gene therapy and mitochondrial function improvement. Novel approaches such as enzyme replacement therapy are also being explored. ClinicalTrials.gov is a resource for finding current trials, and patients should discuss potential participation with their healthcare provider. Questions to ask include eligibility, potential benefits, and risks. New treatments may take several years to become widely available, depending on trial outcomes and regulatory approvals.
How does this condition affect daily life and activities?
Individuals may experience limitations in mobility and self-care due to muscle weakness and coordination issues. Educational accommodations may be necessary due to visual and cognitive impairments. Social and emotional challenges can arise from the condition's impact on independence and peer interactions. Family members often face increased caregiving responsibilities and emotional stress. Supportive measures such as physical therapy, assistive devices, and counseling can significantly enhance quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Costeff Syndrome.
Adam MP, Bick S, Mirzaa GM et al. · Unknown Journal · 1993 · PMID: 20301646
- 2.3-Methylglutaconic aciduria, type 3.
Costeff H, Elpeleg ON · Brain Dev · 1995 · PMID: 7573769
- 3.Ineffectiveness of oral coenzyme Q10 supplementation in 3-methylglutaconic aciduria, type 3.
Costeff H, Apter N, Elpeleg ON et al. · Brain Dev · 1998 · PMID: 9533558
- 4.Iraqi-Jewish kindreds with optic atrophy plus (3-methylglutaconic aciduria type 3) demonstrate linkage disequilibrium with the CTG repeat in the 3' untranslated region of the myotonic dystrophy protein kinase gene.
Nystuen A, Costeff H, Elpeleg ON et al. · Hum Mol Genet · 1997 · PMID: 9097959
- 5.[Costeff syndrome: a syndrome that was described in Israel and the responsible gene discovered by an Israeli doctor].
Fink N, Mouallem M · Harefuah · 2006 · PMID: 16838891
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-27